Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 08, 2026 08:01 ET | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases

60 Degrees Pharma (Nasdaq: SXTP) secures exclusive option to develop castanospermine for tick-borne diseases, expanding its infectious disease pipeline.
June 11, 2026 08:03 ET | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement

60 Degrees Pharma licensed FSU technology for Australian Chestnut Extract production and plans FDA discussions before refiling its NDIN.
March 18, 2026 08:01 ET | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract

60 Degrees files NDIN with FDA for Australian Chestnut Extract; May 25 decision deadline. FSU capsule license option expands commercialization strategy.
January 28, 2026 08:01 ET | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Exercises License Option with Florida State University for Large-Scale Purification of Castanospermine for Non-Rx Use

60 Degrees Pharma licenses FSU technology to purify castanospermine and begins U.S. regulatory steps for non-Rx Australian Chestnut Extract.